Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients

Author(s): Martin C. Boonstra, Hein W. Verspaget, Sjam Ganesh, Frank J.G.M. Kubben, Alexander L. Vahrmeijer, Cornelis J.H. van de Velde, Peter J.K. Kuppen, Paul H.A. Quax, Cornelis F.M. Sier

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 19 , 2011

Become EABM
Become Reviewer
Call for Editor


Since decades the urokinase plasminogen activator (uPA) system has been associated with the invasion of malignant cells. The receptor of urokinase (uPAR) is one of the key players in this proteolytic cascade, because it focuses uPAs proteolytic activity to the cell surface and in addition functions as a signaling receptor. uPAR is highly expressed in virtually all human cancers, suggesting possible clinical applications as diagnostic marker, predictive tool of survival or clinical response, and as a target for therapy and imaging. This review summarizes the possibilities of uPAR in clinical applications for cancer patients.

Keywords: uPAR, diagnosis, prognosis, imaging, targeting, therapy, exosomes, tumor, rheumatoid arthritis, AIDS, ELISA, nano-particles, biopsies, Image-guided surgery (IGS), renal threshold

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [1890 - 1910]
Pages: 21
DOI: 10.2174/138161211796718233
Price: $65

Article Metrics

PDF: 25